middle.news
Paradigm Extends Suspension as Phase 3 Review Nears a Crucial Update
9:45am on Monday 28th of September, 2026 AEST
•
Biotechnology
Read Story
Paradigm Extends Suspension as Phase 3 Review Nears a Crucial Update
9:45am on Monday 28th of September, 2026 AEST
Key Points
Trading suspension extended for PAR and PAROB
Phase 3 interim analysis remains under review
Operational and financial implications still being assessed
Discussions with Obsidian Global continue
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE